ZA811661B - Dipyridamole sustained release formulations and processes for their preparation - Google Patents

Dipyridamole sustained release formulations and processes for their preparation

Info

Publication number
ZA811661B
ZA811661B ZA008101661A ZA811661A ZA811661B ZA 811661 B ZA811661 B ZA 811661B ZA 008101661 A ZA008101661 A ZA 008101661A ZA 811661 A ZA811661 A ZA 811661A ZA 811661 B ZA811661 B ZA 811661B
Authority
ZA
South Africa
Prior art keywords
processes
preparation
sustained release
release formulations
dipyridamole sustained
Prior art date
Application number
ZA008101661A
Other languages
English (en)
Inventor
Peter Gruber
Rolf Brickl
Gerhard Bozler
Herbert Stricker
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of ZA811661B publication Critical patent/ZA811661B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA008101661A 1980-01-12 1981-01-12 Dipyridamole sustained release formulations and processes for their preparation ZA811661B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803000979 DE3000979A1 (de) 1980-01-12 1980-01-12 Neue dipyridamol-retardformen und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
ZA811661B true ZA811661B (en) 1982-09-29

Family

ID=6091926

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA008101661A ZA811661B (en) 1980-01-12 1981-01-12 Dipyridamole sustained release formulations and processes for their preparation

Country Status (32)

Country Link
US (1) US4367217A (fr)
EP (1) EP0032562B1 (fr)
JP (1) JPS56103111A (fr)
AR (1) AR221983A1 (fr)
AT (1) ATE6585T1 (fr)
AU (1) AU539618B2 (fr)
CA (1) CA1148084A (fr)
CS (1) CS232713B2 (fr)
DD (1) DD156943A5 (fr)
DE (2) DE3000979A1 (fr)
DK (1) DK158539C (fr)
ES (1) ES498393A0 (fr)
FI (1) FI78835C (fr)
GB (1) GB2067073B (fr)
GR (1) GR73102B (fr)
HK (1) HK62184A (fr)
HU (1) HU184366B (fr)
IE (1) IE50807B1 (fr)
IL (1) IL61887A (fr)
IN (1) IN155158B (fr)
KE (1) KE3402A (fr)
MA (1) MA19040A1 (fr)
MY (1) MY8500559A (fr)
NO (1) NO157369C (fr)
NZ (1) NZ195994A (fr)
OA (1) OA06720A (fr)
PH (1) PH17063A (fr)
PL (1) PL129290B1 (fr)
PT (1) PT72330B (fr)
SG (1) SG28184G (fr)
YU (1) YU42549B (fr)
ZA (1) ZA811661B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
EP0064485B1 (fr) * 1981-04-27 1985-07-24 Aktiebolaget Hässle Préparation pharmaceutique
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
IE54171B1 (en) * 1982-06-22 1989-07-05 Univ Glasgow Device for introducing nutrients and/or therapeutic materials into ruminant animals
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
HU191542B (en) * 1983-04-08 1987-03-30 Boehringer Ingelheim Ltd Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
WO1988002629A1 (fr) * 1986-10-16 1988-04-21 American Health Products Corporation Composition de didesoxyadenosine-2',3'
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
IL84599A0 (en) * 1986-12-09 1988-04-29 Byk Gulden Lomberg Chem Fab Pharmaceutical composition containing urapidil and process for the preparation thereof
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
ATE120089T1 (de) * 1991-05-20 1995-04-15 Marion Laboratories Inc Mehrschichtige zubereitung mit kontrollierter freisetzung.
SG42869A1 (en) * 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060073201A1 (en) * 1996-03-25 2006-04-06 Wyeth Extended release formulation
JP2000159692A (ja) * 1998-09-25 2000-06-13 Sankyo Co Ltd ＨＭＧ―ＣｏＡレダクタ―ゼ阻害薬含有製剤
AU5758799A (en) * 1998-09-25 2000-04-17 Sankyo Company Limited Hmg-coa reductase inhibitor-containing preparations
PT1207860E (pt) 1999-09-02 2008-01-24 Nostrum Pharmaceuticals Inc Formulação de peletes de libertação controlada
WO2001024781A2 (fr) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessaire a la fonction striatale, ses applications et composes permettant de moduler ce gene
EP1093814A1 (fr) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Utilisation du dipyridamole ou du mopidamol dans la fabrication d'un médicament pour le traitement et la prévention des troubles de la microcirculation dépendants de la fibrine
ES2284643T3 (es) 2000-04-20 2007-11-16 Novartis Ag Composicion de revestimiento enmascarante del sabor.
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
EP1448205B1 (fr) 2001-10-05 2011-03-23 Zalicus Inc. Combinaisons permettant le traitement des troubles immunoinflammatoires
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CN1747734A (zh) * 2003-02-07 2006-03-15 贝林格尔·英格海姆国际有限公司 潘生丁或单哌潘生丁在治疗和预防mmp－9－依赖性疾病中的用途
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
RU2005136383A (ru) 2003-04-24 2007-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06013157A (es) * 2004-05-13 2007-02-13 Boehringer Ingelheim Int Uso de dipiridamol para el tratamiento de la resistencia a los inhibidores de plaquetas.
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (fr) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
ES2546258T3 (es) 2005-03-22 2015-09-22 Stada Arzneimittel Ag Ibuprofeno solubilizado
EP1888071A1 (fr) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Procede pour le traitement de dysfonctionnements sexuels d origine medicamenteuse
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
MX2008002492A (es) * 2005-08-22 2008-04-03 Novartis Ag Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
CN101410093A (zh) 2006-01-27 2009-04-15 欧兰德股份有限公司 包含弱碱性药物和有机酸的药物递送系统
ATE390138T1 (de) 2006-02-09 2008-04-15 Teva Pharma Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung
WO2007128802A2 (fr) * 2006-05-09 2007-11-15 Boehringer Ingelheim International Gmbh Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques
WO2007139753A2 (fr) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Méthodes et compositions pour le traitement de maladies ou d'affections associées à des taux accrus de protéine c réactive, d'interleukine 6 ou d'interféron gamma
WO2008000760A1 (fr) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
AR062321A1 (es) * 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
EP1894561A1 (fr) * 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques de dipyridamole
US20100093754A1 (en) * 2007-03-28 2010-04-15 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009038708A1 (fr) * 2007-09-19 2009-03-26 Combinatorx, Incorporated Régimes thérapeutiques pour le traitement de troubles immunoinflammatoires
CN101938996A (zh) * 2007-12-17 2011-01-05 康宾纳特克斯公司 用于治疗免疫炎症性紊乱的治疗方案
WO2009085306A1 (fr) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Formulations à libération contrôlée de lévodopa et leurs utilisations
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2010036975A2 (fr) * 2008-09-25 2010-04-01 Teva Pharmaceutical Industries Ltd. Formulations de dipyridamole et d'acide acétylsalicylique et leur procédé de préparation
CA2757979A1 (fr) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Compositions de clozapine a liberation controlee
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2361615A1 (fr) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Comprimé à libération prolongée de dipyridamole
EP3054929B1 (fr) 2013-10-07 2020-08-05 Impax Laboratories, LLC Formulations mucoadhésives à libération contrôlée de lévodopa et/ou d'esters de lévodopa et leurs utilisations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL297631A (fr) * 1963-06-03
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1468172A (en) 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB1479655A (en) 1974-03-08 1977-07-13 Beecham Group Ltd Antibiotic preparations
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
LU77353A1 (fr) * 1977-05-16 1979-01-19
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.

Also Published As

Publication number Publication date
GB2067073B (en) 1984-02-15
MY8500559A (en) 1985-12-31
HK62184A (en) 1984-08-17
HU184366B (en) 1984-08-28
EP0032562A1 (fr) 1981-07-29
YU3981A (en) 1983-09-30
OA06720A (fr) 1982-06-30
ES8207428A1 (es) 1982-09-16
DD156943A5 (de) 1982-10-06
NO157369B (no) 1987-11-30
ES498393A0 (es) 1982-09-16
FI78835C (fi) 1989-10-10
DE3067058D1 (en) 1984-04-19
ATE6585T1 (de) 1984-03-15
CS232713B2 (en) 1985-02-14
AR221983A1 (es) 1981-03-31
IE50807B1 (en) 1986-07-23
GB2067073A (en) 1981-07-22
IE810040L (en) 1981-07-12
CS23281A2 (en) 1984-06-18
FI78835B (fi) 1989-06-30
PT72330A (de) 1981-02-01
JPS6116368B2 (fr) 1986-04-30
PH17063A (en) 1984-05-24
PT72330B (de) 1982-07-23
MA19040A1 (fr) 1981-10-01
FI810058L (fi) 1981-07-13
DE3000979A1 (de) 1981-07-23
NO810061L (no) 1981-07-13
EP0032562B1 (fr) 1984-03-14
DK158539B (da) 1990-06-05
US4367217A (en) 1983-01-04
DK9481A (da) 1981-07-13
YU42549B (en) 1988-10-31
PL229157A1 (fr) 1981-09-18
NO157369C (no) 1988-03-16
PL129290B1 (en) 1984-04-30
IL61887A (en) 1984-09-30
GR73102B (fr) 1984-02-02
JPS56103111A (en) 1981-08-18
SG28184G (en) 1985-02-15
IN155158B (fr) 1985-01-05
NZ195994A (en) 1984-04-27
DK158539C (da) 1990-11-05
CA1148084A (fr) 1983-06-14
AU6615681A (en) 1981-07-16
KE3402A (en) 1984-06-08
AU539618B2 (en) 1984-10-11

Similar Documents

Publication Publication Date Title
HK62184A (en) Dipyridamole sustained release formulations and processes for their preparation
DE3068218D1 (en) Controlled release formulations
DE3161708D1 (en) Slow release pesticide formulation
GB2053681B (en) Sustained release pharmaceutical composition
AU545962B2 (en) Centre release buckle
ZA886284B (en) Controlled release formulations
GB2122490B (en) Controlled release formulation
JPS56103110A (en) Sustained release medicinal composition
GB2141023B (en) Delayed release formulations
GB2059766B (en) Controlled release formulations
GB2098867B (en) Sustained release pharmaceutical composition
DE3367089D1 (en) 3-phenoxy-1-azetidinecarboxamides and their use and preparation
DE3171437D1 (en) Prostanoid compounds and their preparation and pharmaceutical formulations
IL62848A (en) Carbapenams and carbapen-2-ems and their preparation
GB8416603D0 (en) Sustained release preparation
GB2117757B (en) Alkylspectinomycins and their preparation
IL62471A0 (en) Hydroquinone-diethers and their use as acaricides
DE3273880D1 (en) Trinitroglycerol sustained release vehicles and preparation therefrom
DE3370796D1 (en) Alpha-iminodiacetonitriles and methods for their preparation
GB8405085D0 (en) Controlled release formulation
ZA816162B (en) Slow release pesticide formulations
DE3374560D1 (en) Cyanoalkylpiperazines and methods for their preparation and use
GB2080307B (en) 6-fluorosteroids and their preparation
DE3378314D1 (en) 2-pyrimidyl alkanesulfonates and methods for their preparation and use
GB8521221D0 (en) Controlled release formulations